Treatment Recommendations for Sleep Maintenance Insomnia
Start with cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, and if pharmacotherapy is needed for nighttime awakenings, use suvorexant, eszopiclone, zolpidem, temazepam, or low-dose doxepin.
Primary Treatment Approach
The American Academy of Sleep Medicine strongly recommends multicomponent CBT-I as the foundational treatment for chronic insomnia disorder in adults 1. This is a STRONG recommendation based on 49 high-quality randomized controlled trials demonstrating clinically meaningful improvements in:
- Sleep quality
- Wake after sleep onset (the core problem in this patient)
- Remission and responder rates
- Sleep latency
CBT-I should be delivered by a trained professional and works effectively regardless of whether comorbid conditions are present 1. The evidence shows CBT-I produces durable benefits with minimal risk, making it superior to pharmacotherapy alone for long-term outcomes.
Pharmacologic Options for Sleep Maintenance
When pharmacotherapy is indicated for frequent nighttime awakenings (sleep maintenance insomnia), the AASM 2017 guideline provides conditional recommendations for several agents 2:
Preferred Medications for Sleep Maintenance:
First-tier options:
- Suvorexant (orexin receptor antagonist): 10-20 mg - specifically indicated for sleep maintenance insomnia 2
- Doxepin (heterocyclic): 3-6 mg - specifically indicated for sleep maintenance insomnia 2
- Eszopiclone (BZD receptor agonist): 2-3 mg - effective for both sleep onset AND maintenance 2
- Zolpidem: 10 mg - effective for both sleep onset AND maintenance 2
- Temazepam (benzodiazepine): 15 mg - effective for both sleep onset AND maintenance 2
Important Distinctions:
Avoid these medications - they have conditional recommendations AGAINST use:
Note: Zaleplon, triazolam, and ramelteon are only recommended for sleep onset insomnia, NOT for nighttime awakenings 2.
Treatment Algorithm
Step 1: Initiate CBT-I as primary treatment
- This addresses the underlying perpetuating factors of insomnia
- Provides sustained benefit without medication risks
- Effective even with psychiatric or medical comorbidities 1
Step 2: If CBT-I alone is insufficient or patient requires faster symptom relief:
- Consider adding pharmacotherapy temporarily
- Choose medication based on the specific pattern: for nighttime awakenings, select from suvorexant, doxepin, eszopiclone, zolpidem, or temazepam
- Recent evidence suggests combination treatment (CBT-I plus medication) may be reasonable for patients who prioritize rapid improvement in total sleep time, though CBT-I alone produces better long-term outcomes 3
Step 3: Ongoing monitoring
- Reassess treatment response regularly
- Plan for medication discontinuation once CBT-I effects are established
- The FDA has approved hypnotics without duration restrictions since 2005, recognizing chronic insomnia often lasts >2 years 4
Critical Caveats
Sleep-related complex behaviors: The FDA requires warnings about sleep-driving and other complex behaviors for all hypnotics 4. Screen for risk factors before prescribing.
Morning residual effects: Particularly relevant for zolpidem - FDA mandated dose reductions in women due to high morning levels causing daytime impairment 4. For this male patient with daytime fatigue, ensure medication choice doesn't worsen this symptom.
Medication selection nuance: For pure sleep maintenance insomnia (nighttime awakenings without difficulty falling asleep initially), suvorexant and low-dose doxepin are specifically designed for this indication and may be preferred over agents that primarily target sleep onset 2.
Access to CBT-I: While CBT-I is first-line, access may be limited by availability of trained providers 5. This practical barrier should not delay treatment - pharmacotherapy can be initiated while arranging CBT-I.